Takeda Pharmaceutical Co, Japan’s largest drugmaker, agreed to buy Millennium Pharmaceuticals Inc for US$8.8 billion, gaining a blood-cancer medicine before the patent on its best-selling Actos diabetes pill expires in 2011.
Stockholders of Cambridge, Massachusetts-based Millennium will receive US$25 a share in cash, 53 percent more than yesterday’s closing price, the two companies said in a statement today. It is Japan’s largest drug acquisition.
Millennium’s cancer treatment Velcade widens the product pipeline Osaka-based Takeda is developing to buffer sales once Actos faces generic competition. Rival Eisai Co agreed in December to buy US drugmaker MGI Pharma Inc for US$3.9 billion to gain more cancer medicines.
“This deal will boost Takeda’s drug-development flow,” said Mitsuo Ohmi, a Tokyo-based analyst at Japan Advisory LLC. “Millennium is a leader in genome medicine, with some promising drugs in early development.”
The US company generated US$265 million in sales last year from Velcade, which is sold in more than 80 countries. Overall revenue climbed 8 percent to US$528 million. Millennium earned US$14.9 million in net income, its first profit since 1998, according to data compiled by Bloomberg.
Takeda fell 2.5 percent to ¥5,410 on the Tokyo Stock Exchange before the announcement. Millennium gained 41 percent in the past year. The takeover premium is more than double the 23 percent Tokyo-based Eisai paid to acquire MGI Pharma.
Japanese drugmakers are expanding outside the world’s second-largest drug market because domestic growth is hampered by a government policy to cut prescription-medicine prices every two years.
“Millennium has strong discovery, development and commercial capabilities led by a well-established management team,” Takeda president Yasuchika Hasegawa said in the statement. “Takeda is committed to becoming a global leader in oncology.”
EUROPEAN TARGETS: The planned Munich center would support TSMC’s European customers to design high-performance, energy-efficient chips, an executive said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday said that it plans to launch a new research-and-development (R&D) center in Munich, Germany, next quarter to assist customers with chip design. TSMC Europe president Paul de Bot made the announcement during a technology symposium in Amsterdam on Tuesday, the chipmaker said. The new Munich center would be the firm’s first chip designing center in Europe, it said. The chipmaker has set up a major R&D center at its base of operations in Hsinchu and plans to create a new one in the US to provide services for major US customers,
The Ministry of Transportation and Communications yesterday said that it would redesign the written portion of the driver’s license exam to make it more rigorous. “We hope that the exam can assess drivers’ understanding of traffic rules, particularly those who take the driver’s license test for the first time. In the past, drivers only needed to cram a book of test questions to pass the written exam,” Minister of Transportation and Communications Chen Shih-kai (陳世凱) told a news conference at the Taoyuan Motor Vehicle Office. “In the future, they would not be able to pass the test unless they study traffic regulations
‘A SURVIVAL QUESTION’: US officials have been urging the opposition KMT and TPP not to block defense spending, especially the special defense budget, an official said The US plans to ramp up weapons sales to Taiwan to a level exceeding US President Donald Trump’s first term as part of an effort to deter China as it intensifies military pressure on the nation, two US officials said on condition of anonymity. If US arms sales do accelerate, it could ease worries about the extent of Trump’s commitment to Taiwan. It would also add new friction to the tense US-China relationship. The officials said they expect US approvals for weapons sales to Taiwan over the next four years to surpass those in Trump’s first term, with one of them saying
BEIJING’S ‘PAWN’: ‘We, as Chinese, should never forget our roots, history, culture,’ Want Want Holdings general manager Tsai Wang-ting said at a summit in China The Mainland Affairs Council (MAC) yesterday condemned Want Want China Times Media Group (旺旺中時媒體集團) for making comments at the Cross-Strait Chinese Culture Summit that it said have damaged Taiwan’s sovereignty, adding that it would investigate if the group had colluded with China in the matter and contravened cross-strait regulations. The council issued a statement after Want Want Holdings (旺旺集團有限公司) general manager Tsai Wang-ting (蔡旺庭), the third son of the group’s founder, Tsai Eng-meng (蔡衍明), said at the summit last week that the group originated in “Chinese Taiwan,” and has developed and prospered in “the motherland.” “We, as Chinese, should never
RSS